CO2020012353A2 - Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos - Google Patents

Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos

Info

Publication number
CO2020012353A2
CO2020012353A2 CONC2020/0012353A CO2020012353A CO2020012353A2 CO 2020012353 A2 CO2020012353 A2 CO 2020012353A2 CO 2020012353 A CO2020012353 A CO 2020012353A CO 2020012353 A2 CO2020012353 A2 CO 2020012353A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical use
heteroaryl substituted
pyrazole compounds
substituted pyrazole
pharmaceutical
Prior art date
Application number
CONC2020/0012353A
Other languages
English (en)
Inventor
Tomoya Miura
Shintaro Hirashima
Tomoyuki Manabe
Tetsuya Iida
Kentaro Sakurai
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CO2020012353A2 publication Critical patent/CO2020012353A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos de pirazol sustituidos con heteroarilo o sus sales farmacéuticamente aceptables que tienen una actividad inhibidora de SGLT1 y son útiles para un fármaco, composiciones farmacéuticas que lo comprenden, y su uso farmacéutico; específicamente, un compuesto de fórmula [X]: en donde R1 es hidrógeno o halógeno, R2 es alquilo de C1-6 o haloalquilo de C1-6, el anillo Het es piridilo sustituido o pirazinilo, pirimidinilo o piridazinilo opcionalmente sustituido, o una sal farmacéuticamente aceptable del mismo, una composición farmacéutica que lo comprende, y su uso farmacéutico se proporciona.
CONC2020/0012353A 2018-04-04 2020-09-30 Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos CO2020012353A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018072557 2018-04-04
PCT/JP2019/014721 WO2019194207A1 (ja) 2018-04-04 2019-04-03 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
CO2020012353A2 true CO2020012353A2 (es) 2021-01-18

Family

ID=68100257

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0012353A CO2020012353A2 (es) 2018-04-04 2020-09-30 Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos

Country Status (19)

Country Link
US (3) US10988462B2 (es)
EP (1) EP3778593A4 (es)
JP (3) JP7130588B2 (es)
KR (1) KR20200139696A (es)
CN (1) CN111902408B (es)
AR (1) AR114465A1 (es)
AU (1) AU2019249560B2 (es)
BR (1) BR112020019939A2 (es)
CA (1) CA3089092A1 (es)
CL (1) CL2020002550A1 (es)
CO (1) CO2020012353A2 (es)
IL (1) IL277686A (es)
MX (1) MX2020010433A (es)
PE (1) PE20201068A1 (es)
PH (1) PH12020551624A1 (es)
SG (1) SG11202009179TA (es)
TW (1) TWI805727B (es)
WO (1) WO2019194207A1 (es)
ZA (1) ZA202006053B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
CA3089092A1 (en) * 2018-04-04 2019-10-10 Japan Tobacco Inc. Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
CA3151909A1 (en) * 2019-09-04 2021-03-11 Japan Tobacco Inc. Therapeutic or prophylactic method for diabetes using combination medicine
CA3152939A1 (en) * 2019-09-04 2021-03-11 Japan Tobacco Inc. Chronic kidney disease treatment or prevention method
CN115209919A (zh) * 2020-03-19 2022-10-18 日本烟草产业株式会社 慢性心衰的治疗或预防方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2515119A1 (en) 2003-02-07 2004-08-19 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivative
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
WO2004113359A1 (ja) * 2003-06-20 2004-12-29 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体、それを含有する医薬組成物及びその製造中間体
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
DE602005017895D1 (de) 2004-07-07 2010-01-07 Merck & Co Inc Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
AU2005305675B2 (en) 2004-11-16 2012-12-13 Gw Pharma Limited New use for cannabinoid
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
JP2008007405A (ja) * 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
WO2006132436A1 (ja) 2005-06-08 2006-12-14 Japan Tobacco Inc. 複素環化合物
JP4137956B2 (ja) 2005-06-08 2008-08-20 日本たばこ産業株式会社 複素環化合物
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
TWI378922B (en) * 2005-10-21 2012-12-11 Mitsubishi Tanabe Pharma Corp A pyrazole compound
EP1991528A2 (en) 2006-01-18 2008-11-19 Siena Biotech S.p.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
US20080027014A1 (en) * 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
JP2010505957A (ja) * 2006-10-10 2010-02-25 アムゲン インコーポレイティッド 糖尿病に対して使用されるｎ−アリールピラゾール化合物
EP2121619A2 (en) 2006-11-24 2009-11-25 AC Immune S.A. Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
US20100183513A1 (en) 2006-11-24 2010-07-22 Wolfgang Froestl N-(methyl) -1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
JP4994295B2 (ja) * 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
WO2009091813A1 (en) 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
EP2349484A2 (en) 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
RU2017144535A (ru) 2010-03-30 2019-02-18 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
WO2011161615A1 (en) * 2010-06-24 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
CN106922146B (zh) * 2014-10-02 2020-05-26 豪夫迈·罗氏有限公司 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
CA3089092A1 (en) * 2018-04-04 2019-10-10 Japan Tobacco Inc. Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof

Also Published As

Publication number Publication date
CL2020002550A1 (es) 2021-01-15
MX2020010433A (es) 2020-10-28
CN111902408B (zh) 2023-11-14
AU2019249560A1 (en) 2020-07-23
JP2022166280A (ja) 2022-11-01
BR112020019939A2 (pt) 2021-01-05
RU2020132318A3 (es) 2022-04-29
KR20200139696A (ko) 2020-12-14
US10988462B2 (en) 2021-04-27
US20220048896A1 (en) 2022-02-17
TWI805727B (zh) 2023-06-21
JP2024050645A (ja) 2024-04-10
JP2019182852A (ja) 2019-10-24
SG11202009179TA (en) 2020-10-29
PE20201068A1 (es) 2020-10-19
EP3778593A4 (en) 2021-12-22
JP7130588B2 (ja) 2022-09-05
PH12020551624A1 (en) 2021-07-12
CA3089092A1 (en) 2019-10-10
AR114465A1 (es) 2020-09-09
IL277686A (en) 2020-11-30
US20240166632A1 (en) 2024-05-23
WO2019194207A1 (ja) 2019-10-10
EP3778593A1 (en) 2021-02-17
US20190330193A1 (en) 2019-10-31
RU2020132318A (ru) 2022-04-29
AU2019249560B2 (en) 2023-10-05
ZA202006053B (en) 2022-03-30
CN111902408A (zh) 2020-11-06
TW201942114A (zh) 2019-11-01

Similar Documents

Publication Publication Date Title
CO2020012353A2 (es) Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
CY1120703T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
CO6852096A2 (es) Métodos plaguicidasque utilizan compuestos de 3-piridil tiazol sustituidos y derivados para combatir las plagas de animales i
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
ECSP16076566A (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su aplicación a inhibidores de irak4
CR20160548A (es) Nuevos Derivados de Pirazolo Pirimidina y su Uso como Inhibidores de MALT1
BR112016016844A2 (pt) Compostos heterocíclicos
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CL2020000363A1 (es) Inhibidores macrocíclicos de mcl-1 y métodos de uso.
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
RS54492B1 (en) KINASE INHIBITOR REGULATING THE SIGNAL PATH OF APOPTOSIS
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
CL2019003857A1 (es) Composiciones y métodos de uso de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida solicitudes relacionadas.
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
CO2017009353A2 (es) Derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
CL2020001020A1 (es) Derivados de bencimidazol y sus usos.
UY36124A (es) Derivados de carboxamida
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
UY36123A (es) Derivados de carboxamida